MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple Sclerosis
MorphoSys Strengthens Patent Position on MOR202 Program
MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology
MorphoSys AG Reports Record Results for Fiscal Year 2011
MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis Trial
AbD Serotec Expands Range of HuCAL Antibodies Used in Clinical Diagnostic Kits
You are now leaving the MorphoSys.com website. This link will take you to a different website. You are solely responsible for your interactions with that website.
Do you wish to proceed ?
Are you a U.S. resident? This portion of the MorphoSys website is intended for U.S. residents only. It is not for individuals living in Germany or other European Union member states.
Do you wish to proceed ?
MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.
Are you a U.S. resident? This portion of the MorphoSys website is intended for U.S. residents only. It is not for individuals living in Germany or other European Union member states.